KF
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research

Kevin Joseph Fitzgerald insider trades: Alnylam Pharmaceuticals (ALNY) stock sales

CSO & EVP, Head of Research, Alnylam Pharmaceuticals Last trade Mar 5, 2026 23 Form 4 filings
$9.6M
Sold, last 12 months
5 sales
$0
Bought, last 12 months
0 buys
13
Open-market trades
since 2024
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Kevin reports to the SEC

Open-market buys and sales

13 trades reported on SEC Form 4, newest first

DateStockTypeValue
Mar 5, 2026ALNY↓ Sell$418K
Mar 3, 2026ALNY↓ Sell$1.1M
Feb 17, 2026ALNY↓ Sell$1.3M
Jan 13, 2026ALNY↓ Sell$1.4M
Nov 17, 2025ALNY↓ Sell$5.5M
Oct 2, 2025ALNY↓ Sell$1.1M
Aug 18, 2025ALNY↓ Sell$633K
Mar 4, 2025ALNY↓ Sell$669K
Feb 28, 2025ALNY↓ Sell$120K
Feb 18, 2025ALNY↓ Sell$531K
Nov 27, 2024ALNY↓ Sell$755K
Aug 12, 2024ALNY↓ Sell$6.0M
Jun 25, 2024ALNY↓ Sell$277K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ALNY insiders

Open-market trades in the last 12 months

About Kevin Joseph Fitzgerald's insider trades

Kevin Joseph Fitzgerald is CSO & EVP, Head of Research at Alnylam Pharmaceuticals (ALNY). Since Jun 25, 2024, Kevin has reported no open-market purchases and 13 sales worth $19.7M on SEC Form 4. In the last 12 months: 5 sales ($9.6M).

Their filings also include grants and awards (19 filings), option exercises (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ALNY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.